DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510 and 522


New Animal Drugs; Change of Sponsor; Zinc Gluconate

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for a new animal drug application (NADA) for zinc gluconate injectable solution from Technology Transfer, Inc., to Ark Sciences, Inc.

DATES: This rule is effective December 21, 2011.

FOR FURTHER INFORMATION CONTACT: Steven D. Vaughn, Center for Veterinary Medicine (HFV–100), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20855, (240) 276–8300, email: steven.vaughn@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

Technology Transfer, Inc., 33 East 33rd St., suite B304, Baltimore, MD 21218 has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 141–217 for NEUTERSOL (zinc gluconate) Injectable Solution to Ark Sciences, Inc., 1101 East 33rd St., suite B304, Baltimore, MD 21218. Accordingly, the Agency is amending the regulations in 21 CFR 522.2690 to reflect the transfer of ownership.

Following this change of sponsorship, Technology Transfer, Inc., is no longer the sponsor of an approved application. Accordingly, § 510.600 (21 CFR part 510) is being amended to remove the entries for this firm.

In addition, Ark Sciences, Inc., is not currently listed in the animal drug regulations as a sponsor of an approved application. Accordingly, § 510.600 is being amended to add entries for this sponsor.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects

21 CFR Part 510


21 CFR Part 522

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 522 are amended as follows:

PART 510—NEW ANIMAL DRUGS

§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

<table>
<thead>
<tr>
<th>Firm name and address</th>
<th>Drug labeler code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ark Sciences, Inc., 1101 East 33rd St., suite B304, Baltimore, MD 21218</td>
<td>076175</td>
</tr>
</tbody>
</table>

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

§ 522.2690 [Amended]

3. The authority citation for 21 CFR part 522 continues to read as follows:


§ 522.2690 [Amended]

4. In paragraph (b) of § 522.2690, remove “067647” and in its place add “076175”.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 558


New Animal Drugs for Use in Animal Feeds; Monensin

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Elanco Animal Health, A Division of Eli Lilly & Co. The supplemental NADA revises a manufacturing specification for monensin free-choice Type C medicated feed for growing cattle on pasture or in dry lot.

DATES: This rule is effective December 21, 2011.

FOR FURTHER INFORMATION CONTACT: Matthew A. Lucia, Center for Veterinary Medicine (HFV–128), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, (240) 276–8116, email: matthew.lucia@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

Elanco Animal Health, A Division of Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285, filed a supplement to NADA 95–735 that provides for use of RUMENSIN 90 (monensin, USP) Type A medicated article in a free-choice Type C medicated feed for growing cattle on pasture or in dry lot (stocker and feeder cattle and dairy and beef replacement heifers). The supplement revises the percent monensin Type A medicated article in the codified free-choice feed specifications to reflect use of a product containing 90.7 grams of monensin per pound. The supplemental NADA is approved as of May 24, 2011, and the regulations in 21 CFR 558.355 are amended to reflect the approval.

Approval of this supplemental NADA did not require review of additional safety or effectiveness data or information. Therefore, a freedom of information summary is not required. The Agency has determined under 21 CFR 25.33 that this action is of a type...